Podcasts about opioid use

Host TJ takes listeners live to the State Capitol in Hartford, Connecticut for Recovery Day. The event features an array of voices, including State Representative Robin Comey, Senator Saud Anwar, and Representatives Patrick Biggins and Devin Kearney, among others, who share their personal stories and legislative efforts to support individuals in recovery. Key discussions include the importance of removing the stigma associated with addiction, the potential benefits of Overdose Prevention Centers, and the need for robust community support and resources. The episode highlights the interconnected nature of recovery, community well-being, and legislative advocacy, emphasizing that recovery is a journey that involves everyone. Recovery Matters Podcast Episode 180 00:00 Introduction to Recovery Matters Podcast00:26 State Representative Robin Comey's Personal Recovery Journey02:54 Senator Saud Anwar on Overdose Prevention07:18 Patrick Biggins on Youth and Recovery08:43 Students for Recovery: Advocacy and Support11:29 Taylor Aitken on Legislative Support for Recovery13:47 Mike Pohl on Community Recovery Efforts17:42 State Representative Devin Kearney on the Importance of Recovery18:39 State Representative Toni Walker on Embracing Recovery21:46 Stacy Sharpentier on Funding and Recovery Support23:56 Conclusion and Resources for Recovery ----Across the Web----

Click here to send us a topic idea or question for Weekend Wisdom.Are you considering adopting or fostering a child who was exposed prenatally to opioids or opioid-use treatment medication, such as Buprenorphine, methadone, and Suboxone? Are you a grandparent or aunt raising a child who was exposed? Join our discussion with Dr. Jennifer McAllister, the Medical Director of the NOWS Follow-Up Clinic at Cincinnati Children's Hospital Medical Center and the Medical Director of the University of Cincinnati Newborn Nursery.In this episode, we discuss:Terminology: What is the difference between opiates and opioids?What are the most common opioids being abused?What are the common treatment medications/drugs given to those with opioid use disorder? What are the brand names for these medications?How do these medications work?Are substance-use medications safe to use during pregnancy?What are the short- and long-term impacts on infants exposed to opioids?What are the short- and long-term impacts of infants exposed to opioid-use medications in pregnancy? Do the impacts differ?Does the dosage of opioid-use medications change the impact they have on the baby?What are the short- and long-term impacts of infants exposed to fentanyl in pregnancy?Is there a safer time for a fetus to be exposed to opioids or opioid-use medications in utero?Is it true that if the child is not born experiencing signs of withdrawal or with drugs in their system, the prognosis is better? Or conversely, if the child is born dependent and has to go through withdrawals, they will suffer more impact from in-utero drug exposure?How dangerous is drug dependency and withdrawal for the infant?How are Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS) treated in babies?If a mom is taking opioid-use medications during her pregnancy, is it recommended that she breastfeed the infant to help with withdrawal? How long does withdrawal in an infant born dependent last?How do you foster attachment while the baby is experiencing withdrawal?You often hear that “early intervention is key” and that a baby's brain can be rewired during the first couple of years with the right treatments or therapy. What exactly does that therapy entail? What strategies should you be using at home with your child with a diagnosis of prenatal drug exposure?When a child has drug exposure and trauma, is it possible to tell the difference in what is causing specific problems, and is the treatment different depending on the cause?Are children who are exposed prenatally to any drug, but specifically to opioids, at a greater risk for substance abuse disorder as teens and adults if they were adopted and not raised in an environment that exposed them to drug use?What are the most common blood-borne diseases that women who have IV drug use?What is the risk to a baby whose mother has HIV or Hepatitis C?Support the showPlease leave us a rating or review. This podcast is produced by www.CreatingaFamily.org. We are a national non-profit with the mission to strengthen and inspire adoptive, foster & kinship parents and the professionals who support them.Creating a Family brings you the following trauma-informed, expert-based content: Weekly podcasts Weekly articles/blog posts Resource pages on all aspects of family building

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##FDA Approves New Cancer DrugThe FDA has approved a new cancer drug that has shown promising results in clinical trials. This drug is expected to provide a much-needed treatment option for patients with this type of cancer.##Major Biotech Company Announces MergerA major biotech company has announced a merger with another company in the industry. This merger is expected to create a powerhouse in the biotech world, with the potential for groundbreaking research and development.##COVID-19 Vaccine UpdateThere have been new developments in the race for a COVID-19 vaccine. Several pharmaceutical companies are in the final stages of clinical trials, and there is hope that a vaccine will be available soon.##Drug Pricing Legislation PassesLegislation aimed at addressing drug pricing has passed in Congress. This legislation is expected to lower the cost of prescription drugs for consumers and improve access to affordable medication.##Biotech Startup Receives FundingA promising biotech startup has secured funding to further its research and development efforts. This funding will allow the company to continue its work on innovative therapies and treatments.##FDA Issues Warning About Opioid UseThe FDA has issued a warning about the dangers of opioid use. This warning comes amid a growing opioid crisis in the United States, and highlights the importance of safe prescribing practices.##New Gene Therapy Shows PromiseA new gene therapy has shown promise in treating a rare genetic disorder. This therapy has the potential to revolutionize treatment for patients with this condition, offering hope for improved outcomes.##Pharma Company Launches Patient Assistance ProgramA pharmaceutical company has launched a patient assistance program to help those in need access necessary medications. This program aims to provide support for patients facing financial barriers to treatment.##Biotech Breakthrough in Alzheimer's ResearchA biotech company has made a breakthrough in Alzheimer's research, uncovering new insights into the disease. This discovery could lead to new treatment options for Alzheimer's patients in the future.

In this episode, Dr Elle Wadsworth talks to Dr Noa Krawczyk from the Department of Population Health at NYU Grossman School of Medicine about her and her co-authors research report on self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities. Noa discusses the current treatments available for opioid use disorder and why psychedelics are having their moment as an alternative medicine, and what people who use opioids found when taking psychedelics with the intention of reducing or stopping their opioid use. · What is Reddit and why is Noa using it to answer her research questions [01:24]· The headline findings of the study [02:17]· The comparison of demographics of Reddit and the wider population of people who use opioids [03:46]· What the current treatments are for opioid use disorder in the US and why people are seeking alternatives [05:22]· Why Ibogaine stands out as a prominent psychedelic in the discussion [08:12]· The mechanisms of action found in the analysis [09:45]· The benefits and drawbacks of using psychedelics [13:26]· What we can take from the paper for policy and practice [15:28]About Elle Wadsworth: Elle is an academic fellow with the Society for the Study of Addiction. She is based at the University of Bath and her research interests include drug policy, cannabis legalisation, and public health. Elle is also a senior analyst at RAND Europe, working on projects focusing on national and international drug policies. About Noa Krawczyk: Noa Krawczyk, PhD, is an assistant professor in the Department of Population Health at NYU Grossman School of Medicine and Associate Director of the NYU Langone Center for Opioid Epidemiology and Policy. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorder at the individual, program, and policy levels. Her work centers on bridging research and practice by collaborating with drug user organizations, health system leaders, public health and government agencies, and advancing science that can help inform evidence-based policies and practices that reduce harm and promote well being.About co-author Megan Miller: Megan Miller, MPH, is a Research Coordinator in the Center for Opioid Epidemiology and Policy at NYU Grossman School of Medicine and served as the primary data analyst for the Reddit study. She holds an MPH from the University of North Carolina at Chapel Hill. NK receives fees as an expert witness in ongoing opioid litigation. MM has no conflicts of interest to declare.Original article: Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities https://doi.org/10.1111/add.16767 The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal. The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

Concern about the uptick of opioid use in the workplace. The Drug Detection Agency released its drug testing findings in the three months to December. Cannabis continues to be the most prevalent substance detected in workplace drug tests, accounting for 59 per cent of cases. But CEO Glen Dobson told Andrew Dickens 12 percent involved opioids, which is the most high-risk drug in the workplace. He says we're starting to see the trends we see internationally, like the widespread Fentanyl issue in the US. See omnystudio.com/listener for privacy information.

Hosted by RAPM Editor Eric Schwenk, MD, this episode of RAPM Focus welcomes RAPM Associate Editor Mark Bicket, MD, PhD, and medical student Sama Ramo following the recent publication of their original research paper, “Risk Factors for Persistent Postoperative Opioid Use: An Entity Distinct from Chronic Postsurgical Pain,” included in the February 2025 special edition of RAPM, titled “Tackling the Challenge of Chronic Postsurgical Pain.” Persistent postoperative opioid use results when patients continue to take prescription opioids well beyond the time their pain after surgery would be expected to resolve. In some cases, this is a couple days; in other cases, this is several weeks. There are many challenges associated with prescription opioid use, including the lack of a truly safe dose, so there is risk across the continuum. Patients facing persistent postoperative opioid use potentially confront worse outcomes, higher rates of health care utilization, and higher rates of mortality compared to patients not enduring persistent postoperative opioid use. Dr. Mark Bicket is an associate professor of anesthesiology with tenure at the University of Michigan and a joint appointment in the Department of Health Management and Policy at the School of Public Health. Additionally, he is co-director of the Overdose Prevention Engagement Network (OPEN). A clinician-scientist and practicing physician anesthesiologist, Dr. Bicket has pioneered evidence-based approaches to reduce opioid-related harms and improve the treatment of persons who experience pain. He currently leads an NIH R01 study examining pain-related outcomes for persons with opioid use disorder who have surgery and serves as PI for two pragmatic trials funded by the Patient-Centered Outcomes Research Institute including the CARES study, an international randomized clinical trial examining commonly prescribed treatments for postoperative pain. He previously served on the National Academy of Medicine ad hoc committee on evidence for opioid prescribing guidelines in 2018-2019 and a workshop on opioid disposal in 2023. Dr. Bicket has advised the White House, FDA, CMS, state governments, and national organizations on pain and opioid issues. His research, which includes 120 peer-reviewed articles, has appeared in JAMA, NEJM, and BMJ, and has been supported by the Foundation for Anesthesia Education and Research (FAER), SAMHSA, and CDC. Sama Ramo is a second-year medical student at Oakland University William Beaumont School of Medicine. She is a Foundation for Anesthesia Education and Research scholar. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.

Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use by SAEM

Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use by SAEM

  Evaluation and Credit:  https://www.surveymonkey.com/r/medchat74 Target Audience This activity is targeted toward primary care physicians and advanced providers. Statement of Need With the 2023 DEA regulation changes, physicians can now treat patients with Opioid Use Disorder (OUD) without requiring an X waiver. As the demand for treatment providers rises, primary care providers are pivotal in addressing this gap by initiating OUD treatments. Given that primary care often serves as the first point of contact within the healthcare system, it's crucial for providers to identify patients who could benefit from OUD treatment. However, many providers fail to recognize these patients and may refer them elsewhere, missing opportunities for immediate care. Objectives Describe screening guidelines and key diagnostic criteria for Opioid Use Disorder (OUD) Discuss effective medications for the treatment of opioid use disorder (MOUD). Review treatment strategies for MOUD treatment including guidelines for detox in the primary care setting. ModeratorJames T. Jennings, M.D., MBA Executive Medical Director Norton Medical Group Norton Healthcare Louisville, Kentucky SpeakerKelly Cooper, M.D., MPH, FASAM Medical Director Addiction Services Norton Behavioral Medicine Norton Healthcare Louisville, Kentucky  Moderator, Speaker and Planner Disclosures  The planners, moderator and speaker of this activity do not have any relevant financial relationships with ineligible companies to disclose.   Commercial Support  There was no commercial support for this activity.  Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. HB1This program has been approved for .75 HB1 credit hours by the Kentucky Board of Medical Licensure, ID# 1124-H.75-NHC11a.  For more information about continuing medical education, please send an email to cme@nortonhealthcare.org.  Nursing CreditsNorton Healthcare Institute for Education and Development is approved with distinction as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.75 ANCC CE contact hours. Norton Healthcare is also a Kentucky Board of Nursing (KBN) approved provider. This activity has also been approved by Norton Healthcare for 0.75 KBN Pharmacology contact hour, which expires 12/31/2026. KBN approval of a continuing education provider does not constitute endorsement of program content.  This activity/session meets 0.75 CE contact hour (of the 3.0 contact hour annual requirement) of approved pain management and addiction disorder CE required by the Kentucky Board of Nursing (KBN) for annual license renewal for APRNs that are registered with the DEA and have a Prescription Drug Monitoring Program (PDMP) account– 201 KAR 20:215.” – 4-0002-12-26-004. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.  For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Resources for Additional Study/References Reframing conceptualizations of primary care involvement in opioid use disorder treatment; Chiu and Sud BMC Primary Care (2024) 25:356. Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics; J Gen Intern Med 38(2):332–40; DOI: 10.1007/s11606-022-07675-2.   Resources American Society of Addiction Medicine Provider Clinical Support System U.S. Centers for Disease Control and Prevention    Date of Original Release | Jan. 2025; Information is current as of the time of recording. Course Termination Date | Jan. 2028 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

A one-size-fits-all approach to caring for patients with pain is not a prudent way to manage care. In this episode, physicians discuss the recent updates the Federation of State Medical Boards made to its recommendations relating to opioids and pain care. Physicians from the Federation include Humayun Chaudhry, DO, president and CEO, Sarvam TerKonda, MD, past chair, and Sherif Zaafran, MD. They join Dr. Michael Suk, Chair of the AMA Board of Trustees to discuss the updates.    ⭐⭐⭐⭐⭐

The guideline is published in the Canadian Medical Association Journal. The lead author on this updated is Igor Yakovenko. He is an associate professor in the Department of Psychology and Neuroscience and the Department of Psychiatry at Dalhousie University, where he studies addictive behaviours. Mainstreet's Alex Guye. To hear more about the update and what changes were made to its recommendations, Alex Guye gave professor Yakovenko a call. Here's part of their conversation.

Join Dr. Clancy and his guests, Drs. Elizabeth Amelon, David Dickens, and Rachel Kinn as they discuss guidance for clinicians in using opiods for end of life pediatric patients.  CME Credit Available:  https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=71737  Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Elizabeth Amelon, MD Pediatric Clinical Pharmacy Manager University of Iowa Health Care David Dickens, MD Clinical Professor of Pediatrics - Hematology/Oncology University of Iowa Dance Marathon Endowed Chair in Pediatric Oncology, Clinical and Tranlational Research Clinical Director of Pediatric Oncology Services University of Iowa Health Care Rachel Kinn, MD Clinical Pharmacy Specialist University of Iowa Health Care Financial Disclosures:  Dr. Gerard Clancy, his guests and the members of the planning committee for Rounding@IOWA have no relevant financial relationships to disclose. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 0.75 ANCC contact hours. Pharmacist: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 0.75 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit.  UAN: JA0000310-0000-24-087-H01-P Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of participation will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Breaking News: FDA Approves New Cancer DrugIn a groundbreaking development, the FDA has approved a new cancer drug that has shown promising results in clinical trials. The drug is expected to provide hope for patients with advanced forms of cancer, offering a potential lifeline where traditional treatments have failed. This approval marks a significant step forward in the fight against cancer and has the potential to save countless lives.##Major Acquisition in Biotech IndustryIn a surprising turn of events, a major acquisition has taken place in the biotech industry. This acquisition is set to shake up the market and create new opportunities for growth and innovation. Industry experts are closely watching to see how this acquisition will impact the competitive landscape and what it means for the future of biotech companies involved.##Breakthrough Research in Gene TherapyExciting news has emerged in the field of gene therapy, with researchers announcing a major breakthrough that could revolutionize treatment options for genetic diseases. This groundbreaking research has the potential to transform the lives of millions of patients worldwide, offering new hope for those suffering from previously untreatable conditions. The implications of this research are far-reaching and could have a profound impact on the future of medicine.##FDA Issues Warning About Opioid UseIn a move to address the ongoing opioid crisis, the FDA has issued a warning about the dangers of opioid use and abuse. This warning comes in response to rising rates of addiction and overdose related to opioid medications. The FDA is urging healthcare providers and patients to exercise caution when prescribing or taking opioids, emphasizing the importance of responsible use and proper monitoring. This warning serves as a reminder of the critical need for continued vigilance in combatting this public health crisis.##New Partnership Formed to Combat Infectious DiseasesA new partnership has been formed between leading pharmaceutical companies and public health organizations to combat infectious diseases on a global scale. This collaboration aims to leverage resources and expertise to develop innovative solutions for preventing and treating infectious diseases, with a focus on addressing emerging threats and improving access to healthcare for vulnerable populations. The formation of this partnership signals a united front in the fight against infectious diseases and represents a significant step forward in global health efforts.##ConclusionThese recent developments highlight the dynamic and ever-evolving nature of the Pharma and Biotech industries. From groundbreaking approvals to major acquisitions, breakthrough research, and important warnings, there is no shortage of news shaping the future of healthcare. As we continue to navigate these changes, it is clear that collaboration, innovation, and a commitment to improving patient outcomes will be key drivers of success in these industries. Stay tuned for more updates on the latest news and trends in Pharma and Biotech.

Oct. 16, 2024 - Coalition of Medication-Assisted Treatment Providers and Advocates President Allegra Schorr explains how an updated federal regulation will make it easier to treat New Yorkers for opioid abuse.

Get the book, Ending the Crisis: Mayo Clinic's Guide to Opioid Addiction and Safe Opioid Use About The Author Dr. Holly Geyer, MD is an Addiction Medicine Specialist at Mayo Clinic in Scottsdale, Arizona and the physician lead of the MCA Opioid Stewardship Program, and chairs the ‘School Training Overdose Preparedness and Intelligence Taskforce' (STOP-IT), a 60+ member multidisciplinary working group charged with developing a comprehensive and sustainable school opioid overdose preparation plan and toolkit for AZ schools. She is widely published in high-impact scientific journals and book chapters, and maintains an active international lecture schedule. She additionally serves as a Physician Director of the Mayo Clinic Physician Assistant Fellowship program.   This episode of Principal Center Radio is sponsored by IXL, the most widely used online learning and teaching platform for K-12. Discover the power of data-driven instruction in your school with IXL—it gives you everything you need to maximize learning, from a comprehensive curriculum to meaningful school-wide data. Visit IXL.com/center to lead your school towards data-driven excellence today.   

In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest Valeriy Shubinets, MD, discuss the following articles from the September 2024 issue:  “Predicting Persistent Opioid Use after Hand Surgery: A Machine Learning Approach” by Baxter, Ho, Byrd, et al. Read the article for FREE: https://bit.ly/PredictingOpioidUse Special guest, Dr. Valeriy Shubinets, is a faculty member at The Curtis National Hand Center and MedStar Health. Originally from Ukraine, he obtained his medical degree from Harvard Medical School. He was awarded the Howard Hughes Medical Institute fellowship for a research year before he completed his plastic surgery residency at the University of Pennsylvania, followed by an orthopedic hand fellowship at The Curtis National Hand Center and Union Memorial Hospital. Dr. Shubinets has a diverse clinical practice in hand surgery with a focus on reconstruction and microsurgery including very complex replantations, and he also conducts research to better understand vascular anatomy.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCSept24Collection

This week the hosts look at research that shows medicinal cannabis can safely relieve cancer pain and curb total meds and opioid use, and they discuss how artificial intelligence may […]

This week the hosts look at research that shows medicinal cannabis can safely relieve cancer pain and curb total meds and opioid use, and they discuss how artificial intelligence may […]

Association of regular opioid use with incident dementia and neuroimaging markers of brain health in chronic pain patients: analysis of UK Biobank The American Journal of Geriatric Psychiatry In this cohort study, researchers examine the association between regular opioid use in patients with chronic pain and development of dementia over 15 years of follow-up. Regular opioid use versus non-opioid analgesic use in this population was associated with increased risk of incident dementia (HR=1.18 CL,1.08-1.30). In addition, there appeared a dose-dependent response with those receiving more prescriptions being more likely to develop dementia: 1-5 prescriptions OR=1.21, 6-20 prescriptions OR=1.27, and >20 prescriptions OR=1.43. Finally, in brain imaging, those with regular opioid use exhibited lower total gray matter and higher white matter hyperintensities. While additional research may be needed to support causality, the authors suggest these findings support caution in regular use of opioids for chronic pain.  Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Authorities in Australia are trying to avoid a crisis in the use of opioid prescription drugs in Australia, by imposing restrictions by 2020 to limit their supply. - Pihak berwenang di Australia berupaya menghindari krisis penggunaan obat-obatan resep opioid di Australia, dengan menerapkan pembatasan pada tahun 2020 untuk membatasi pasokan mereka.

Most of us might be familiar with the term 'the war on drugs'. In the US, it's been waged since the 1970s, when then President Richard Nixon signed the Controlled Substances Act and declared drug abuse as “public enemy number one.” But today, it's not so much illicit drugs but prescription medication that the US is fighting, with deaths from prescription opioids reaching crisis levels. Authorities in Australia have been keen to avoid a similar emergency here, introducing restrictions in 2020 to limit their supply. In this episode of the Too Hard Basket series, SBS looks at how effective these changes have been so far - and what else needs to be done. This is the first in a three-part series investigating drugs in Australia.

Welcome back to this week's #FridayReview where I can't wait to share with you the best of the week!   I'm looking forward to reviewing:   Reimagining Health Summit Dates! Apple Watch (product review) Latest in BioTracking & Wearables Dementia & Opioid Use(research) Purple Foods & Diabetes (research)   For all the details tune into this week's #CabralConcept 2982. Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/2982 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In Australia, the misuse of prescription opioids has been a longstanding problem. At one point the nation recorded the world's ninth highest per capita consumption in the world. But changes to prescribing rules in 2020 appear to have been effective in reducing their use.

Research from the University of Auckland highlights a rise in the prescription and use of opioids in New Zealand, particularly among post-surgery and older adult patients. Producer Ezra spoke to Pharmacy Lecturer Dr Jay Gong, and Clinical Pharmacist, Hoda Fahmy, from the University of Auckland, about the research and its implications on older adult and post-surgery patients.

New research from the University of Auckland has found there has been an increase of opioid use in older people and patients after surgery.  Health records for more than 800,000 people over 65 show from 2007 to 2018, there has been an increase in prescriptions. Records show a rate of persistent use of people still using opioids 90 days after surgery at 9.1%.  Lead Researcher Hoda Fahmy tells Mike Hosking the rate of persistent use is a significant percentage and that not all patients on opioids may need them.   LISTEN ABOVE See omnystudio.com/listener for privacy information.

Julia Branger, PharmD discusses use of buprenorphine in the perioperative period. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Data describing the relationship between specific traumatic injuries and opioid use is lacking, which is why RAPM is so delighted to support the work of Matthew Mauck, MD, PhD, and colleagues. In this episode of RAPM Focus, RAPM Editor-in-Chief Brian Sites, MD, discusses “Incidence of persistent opioid use following traumatic injury with Dr. Mauck, first published in June 2023. Dr. Mauck is an assistant professor and vice chair of research for the University of North Carolina's department of anesthesiology. He is a practicing pain physician, and his main research focus is on preventing the transition of acute to chronic pain following traumatic injury. Upon individuals hospitalized after surgery, up to 60% continue to experience chronic pain at 12 months. Dr. Mauck and colleagues used insurance claims data from over a 20-year period to estimate the incidents of new persistent opioid use in three hospitalized trauma populations. Burn injury, motor vehicle collision, and orthopedic injury. New persistent opioid use is defined as the receipt of greater than one opioid prescription 90-180 days following injury in an individual with no opioid prescriptions during the year prior. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on Twitter @RAPMOnline. #opioidprescription #opioiduse #persistentopioiduse #traumaticinjury #regionalanesthesia #acutepain #chronicpain #anesthesia #pain #painmanagement #MedEd #medicine

Dr. Joshua Lee, MD is a highly accomplished clinician and researcher specializing in medication-assisted treatment of alcohol and opioid use disorders. Josh is passionate about making evidence-based treatment accessible to those seeking to drink less or achieve sobriety. His extensive experience includes conducting clinical trials on naltrexone and buprenorphine in primary care, criminal justice, and community settings. He also treats patients struggling with addiction as a primary care physician. Josh is a Professor of Population Health and Medicine at NYU Grossman School of Medicine, directs the ACGME-accredited Addiction Medicine Fellowship, and leads research initiatives focused on justice and community outcomes. He is also Chief Clinical Advisor at Oar Health, a telemedicine platform that makes medication-assisted treatment for alcohol use disorder convenient and private.HealthCare UnTold thanks Dr. Joshua Lee for sharing his career journey with us and his commitment to helping those with substance use disorders to seek health care and effective medication.#oarhealth.com#drjosualee#NYUgrossmanschoolofmedicine#aa#treatmentworks#healthcareuntold@gmail.com

Episode: January 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Gregory L. Alexander, PhD, RN; Micah Segelman, PhD; Paul Katz, MD, CMD (co-editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and co-editor-in-chief Paul Katz, MD, CMD, will talk with two authors, Gregory L. Alexander, PhD, RN and Micah Segelman, PhD, about their recent JAMDA articles. First, Gregory L. Alexander, PhD, RN, will discuss a survey of technology abandonment in US nursing homes. Then Micah Segelman, PhD, will report on the outcomes for long stay nursing facility residents following on-site acute care under a CMS initiative. Finally, co-editor-in-chief Paul Katz, MD, CMD, will review a study examining the use of psychotropic, anticonvulsant, and opioid medications in assisted living residents before and during the COVID-19 pandemic. Articles Referenced: A Survey of Technology Abandonment in US Nursing Homes Outcomes for Long-Stay Nursing Facility Residents Following On-Site Acute Care Under a CMS Initiative Psychotropic, Anticonvulsant, and Opioid Use in Assisted Living Residents Before and During the COVID-19 Pandemic Date Recorded: January 22, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for AMDA On-The-Go and affiliate podcast episodes as follows: Claim CMD Credit

In the first hour, Brad Ferland is joined by WCAX multimedia journalist and health reporter Laura Ullman and Melinda White of Turning Point of Franklin County. They discuss Laura's three-part series: "WCAX Investigates: “Obstacles to opioid use recovery.”

In Renae's backyard, people she loves trust that they can use drugs without fear of being raped, robbed or dying after an overdose. Renae keeps watch and revives people, if needed. 10 years ago, Renae couldn't have imagined doing this. That was before her own daughter got addicted to opioids.

Illegal drug possession is against the law and many drug addicts turn to crime to support their habit. Others, impacted by the influence of illegal drugs, commit other crimes, including crimes of violence. One side says we should lock them up so they don't continue to victimize the public, the other end of the spectrum claims that drug treatment is the answer to minimizing crime and healing the addict. What do you think?======================================= Click here!  http://Aura.com/profilingevil to get a 14-day free trial and protect yourself against America's fastest growing crime.  Get 10% Off your TruthFinder subscription with code EVIL10 at checkout: https://truthfinder.pxf.io/c/3466408/1404760/15694  

Title: Opioid Use Disorders in Pediatrics   Target Audience This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards.   Objectives: Upon completion of this activity, participants should be able to:               Review definition and epidemiology of Opioid Use Disorders (OUD). 2.       Review mechanism of action of Opioids. 3.       Review medications for treatment of Opioid Use Disorders (OUD) and harm reduction principles. 4.       Review considerations for when and adolescent is admitted to the hospital who happens to have OUD. Faculty:  Planning Committee: Allison Williams MD, — Assistant Professor of Pediatrics, Division of Pediatric Hospital Medicine, UPMC Children's Hospital of Pittsburgh   Course Directors: Tony R. Tarchichi MD — Assistant Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine Dr. Tarchichi has disclosed he was a member of the Advisory Board for meningococcal vaccine in immunocompromised patient for Sanofi Corp   Maggie Sheng, MD —  Clinical Instructor, Department of Internal Medicine at the University of Pittsburgh School of Medicine.    Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.   Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.   Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.   Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.   Released 12/1/2023,  Expires 12/1/2026   The direct link to the course is provided below: COMING SOON!!

If you needed further evidence that politicians don't understand the fentanyl crisis they helped to create, Senator Joe Manchin has you covered. We already sell some body fluids in select circumstances; will the day come when we sell body parts to the highest bidder?

Dr. Kim Lombardy shares a story of a chronic back pain patient who was prescribed and became addicted to opioids.  Dr. Lombardy describes this patient's condition and how he successfully treated his back pain with Cox Technic eliminating his dependence on opioids. Dr. Kim Lombardy is a native of Sandusky, Ohio. After suffering from chronic pain and illness, stemming from a childhood accident, and being under medical care for 20 years, he was referred to a local Sandusky chiropractor, Dr. Vince Darr. After a series of spinal adjustments, Dr. Lombardy's pain began to recede, and his health was restored. He was so impressed that he changed his major from Pre-Veterinary Medicine to Pre-Chiropractic. After completing his undergraduate studies at Bowling Green State University, he enrolled in Sherman College of Chiropractic in Spartanburg, SC, where he graduated in 1980. Dr. Lombardy moved to Augusta, GA, and opened Woodland Chiropractic Life Center which later became Lombardy Chiropractic Clinic. He practiced for 29 years before being appointed Assistant Clinical Professor in the Orthopedic Department of the Medical College of Georgia, the first chiropractor to obtain that position in the history of MCG.   After two years he returned to private practice. Dr. Lombardy served as Vice-President of the Georgia Chiropractic Association for three years. He has the highest level of training in Activator Methods (painless instrument adjusting) and Cox Technic for disc problems. He has also studied Advanced Clinical Nutrition to help the body heal from the inside as well. Dr. Lombardy brings over 40 years of clinical experience to better help patients regain their health naturally. He is married to Edna Lombardy, and they have four children and nine grandchildren. They are members of St. Mary on the Hill Catholic Church.   Resources:   To schedule an appointment with Dr. Lombardy   Find a Back Doctor   Opioid Use Reduction in Failed Back Surgery Syndrome Patients at Three Months Utilizing Manual Spinal Decompression Manipulation   The Cox 8 Table by Haven Medical  

  Lead Story: Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us Research Program 

The opioid scourge is as much a rural as an urban problem. The Health Resources and Services Administration (HRSA), part of Health and Human Services, has spent five years and hundreds of millions of dollars in grants to rural health services providers to help battle a nearly overwhelming problem. For its work, the HRSA team leading the effort has been named a finalist in the Service to America Medals program. Federal Drive Host Tom Temin spoke with two members in-studio: HRSA's Rural Strategic Initiatives Director, Megan Meacham and Team Lead Sarah O'Donnell. (Deputy director Allison Hutchings is the third member). Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The opioid scourge is as much a rural as an urban problem. The Health Resources and Services Administration (HRSA), part of Health and Human Services, has spent five years and hundreds of millions of dollars in grants to rural health services providers to help battle a nearly overwhelming problem. For its work, the HRSA team leading the effort has been named a finalist in the Service to America Medals program. Federal Drive Host Tom Temin spoke with two members in-studio: HRSA's Rural Strategic Initiatives Director, Megan Meacham and Team Lead Sarah O'Donnell. (Deputy director Allison Hutchings is the third member). Learn more about your ad choices. Visit megaphone.fm/adchoices

I'm not sure that's actually a thing.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Corri, a harm reduction advocate, shares her journey of personal recovery from substance use and self-destructive behaviors. They discuss their role as the manager of drug user health at Nastad, a nonprofit organization focusing on harm reduction. Corri explains that Nastad operates a Technical Assistance Center for Harm Reduction, providing resources and training to support harm reduction practices for various organizations and individuals. They introduce harm reduction strategies like syringe exchange programs and safe consumption sites. Syringe exchange programs allow individuals to safely dispose of used syringes and obtain sterile ones, reducing the spread of infectious diseases and encouraging treatment. Safe consumption sites provide supervised spaces for substance use, with medical professionals present to prevent overdoses and offer resources. Phil inquires about the arguments against safe consumption sites, to which Corri emphasizes the importance of compassion and support over shame and stigma. They believe that meeting individuals where they are and providing a nonjudgmental environment can make a significant positive impact. Corri opens up about her personal recovery journey, their struggles with opioid use, and other self-destructive behaviors. They found recovery through therapy, community support, and engaging in creative activities such as yoga, aerial arts, and art journaling. Corri is open about occasional recreational substance use like marijuana and wine, which they view within a harm reduction context. They discuss their upcoming presentation at the Multiple Pathways to Recovery conference in August, where they plans to delve into harm reduction principles and how they can be incorporated into different practices. Throughout the conversation, Corri emphasizes the importance of harm reduction as a way to provide support, compassion, and resources to individuals struggling with substance use and promote their overall well-being.

Dr. Matt Starr, vitreoretinal surgeon at Mayo Clinic, joins us to talk about standardized prescribing guidelines for opioid use after ophthalmic surgery. This is a hugely important topic within the house of medicine and for ophthalmologists. Erick and Dr. Starr talk about viewing projects through the lens of quality improvement, how we learn from our practice patterns, and how we can make a difference for our patients.  Impact of Standardized Prescribing Guidelines on Postoperative Opioid Prescriptions after Ophthalmic Surgery Opioids and ophthalmology: review of the current literature Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com  Follow and reach out to us on Twitter: @mayocliniceye 

This week the hosts look at research that shows medicinal cannabis can safely relieve cancer pain and curb total meds and opioid use, and they discuss how artificial intelligence may change medicine. Plus, they share a healthy recipe for Cobb salad wraps.

This week the hosts look at research that shows medicinal cannabis can safely relieve cancer pain and curb total meds and opioid use, and they discuss how artificial intelligence may change medicine. Plus, they share a healthy recipe for Cobb salad wraps.

Editor's Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the May 23/30, 2023, issue. Related Content: Audio Highlights

Moderator: James Rathmell, M.D. Participants: Kai Kuck, Ph.D. and Karim Shiraz Ladha, M.D. Articles Discussed: Prolonged Opioid Use and Pain Outcome and Associated Factors after Surgery Under General Anesthesia: A Prospective Cohort Association Multicenter Study Uncoupling Pain and Opioid Use after Surgery Transcript

Do you, or someone you know, struggle with opioid addiction? If so, join us for this episode as we take an honest look at the challenges of opioid addiction in the United States today. Our special guest, Jaeda Chabot, shares her real-life journey from addiction to sobriety and shares what it was that helped her to recover. We then shift the discussion toward prevention as special guest Lauren Bozarth, a Health Communications Campaign Administrator at Prevention First, shares more about the public awareness and prevention campaigns she creates to help drive awareness and recovery. Also, joining the discussion is special guest David Mastropietro, a pharmacist and researcher of abuse-deterrent formulations who discusses his research around developing medications that help prevent drug-users from becoming addicted to prescription drugs – like opioids – in the first place. He shares the unfortunate challenges we face as a nation that are preventing these new pharmaceutical developments from being available in the market. David also offers helpful tips for what to do in the event someone you know is found overdosing. What you will learn in this episode could save someone's life – maybe even your own. Do you have an idea for an upcoming episode? If so, let us know by sending an email to un.believer.inbetweener@gmail.com.   * The nasal spray mentioned in the show is called Narcan.

Let's review a clinical trial of medical cannabis use in chronic pain patients with the goal of reducing daily MME dose.

Frailty in Vasculitis Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at ACR22 Convergence. Lupus, Sex and STDs Dr. Kathryn Dao discusses abstract 0939 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0939: Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for Giant Cell Arteritis Dr. Richard Conway discusses abstract 0470, being presented during Poster Session A on Saturday, November 12, 2022 at the ACR 2022 meeting.  Abstract 0470: Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented during Poster Session C on Sunday, November 13, 2022 at the ACR 2022 meeting.  Abstract 1207: Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid Should You Repeat the ENA Panel? Dr. Kathryn Dao discusses abstract 0725, presented at ACR22 Convergence.  Abstract 0725: Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit To Beta Block or Not in GCA and Large Vessel Vasculitis Dr. Patricia Harkins discusses abstract 0477 presented on Saturday, November 12, 2022, at ACR22 Convergence. Abstract 0477: Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis? A Novel Treatment Response Measurement Tool for Lupus Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process Sarilumab in Polymyalgia Rheumatica: Results from Phase 3 Trial Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA.  Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) Welcome to ACR 2022 Dr. Jack Cush, Executive Editor of RheumNow, welcomes you to Philadelphia for ACR22 Convergence! 2022 ACR/EULAR Classification Criteria for GCA Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA. Gender in AxSpa Dr. Peter Nash, Philadelphia Do Disease Activity Measures Really Capture AS in Women? Dr. Rachel Tate interviews Dr. Sinead Mcguire about Abstract 0406, presented at ACR22 Convergence in Philadelphia, PA. Abstract 0406: https://acrabstracts.org/abstract/are-the-basdai-basfi-capturing-the-full-impact-of-disease-activity-on-quality-of-life-in-women-with-axial-spondyloarthritis/ Dr Aurelie Najm  Opoids and health care utilization in PsA and AS Abstract 402 Poor Medication Adherence in SLE  and How to Improve It Dr. Janet Pope discusses three abstracts presented at the ACR22 Convergence meeting in Philadelphia, PA. 0343: Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort 0115: Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff 0063: Implementability of a SLE Medication Adherence Intervention Sputum anti-CCP the new diagnostic test in at-risk RA? Dr. Aurelie Najm discusses abstract 0533 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0533: Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity Drs Cush and Fava:  Urinary Biomarkers in Lupus Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria Social Media in Rheumatology Academia Dr. Kathryn Dao, Dallas Jorena Lim, third-year medical student, UTSW, Dallas Abstract 0220 Treatment Choices and Mortality in RA ILd Dr. Julian Segen, Philadephia Dr. Bryant England, Philadephia Dr Tate PsA Cycling or Switching MOAs with Dr  Ogdie Abstracts 1600 and 402. Dr Cassy Sims The Impact of Upacitinib vs  Adalimumab in Psoriatic Arthritis using RAPID Abstract 192. Urinary Biomarkers in Lupus Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria Dr Janet Pope Switching from a JAK Inhibiter Abstract 0274. Dr Yusof Effect of voclosporin in Class 5 lupus nephritis Abstract 0355. Best of PsA Dr. Rachel Tate Drs Yusof and Sexena Breakthrough COVID infection in a lupus cohort during Omicron era Session # 12S119. PsA Cycling or Switching MOAs Dr. Rachel Tate interviews Dr. Alexis Ogdie at ACR22 Convergence in Philadelphia, PA.  Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Abstract 402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at ACR22 Convergence.

Can we alter neonatal gut microbiome to prevent spondyloarthritis? Dr Chao discusses Abstract 0868 at the ACR22 Convergence meeting.  Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome JAK vs TNF inhibitor Infections in RA Dr. David Liew discusses abstract 0302 at ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis Opioid and Neuropathic Use After Initiating btsDMARDs in RA Dr. Julian Segan discusses Abstract 0925 at the ACR22 Convergence meeting. The Dietary Intervention in PsA (DIPSA) StudyDr. Patricia Harkins talks with Professor Lihi Eder about abstract 1007 at the ACR22 Convergence meeting.  Abstract 1007: Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Abstract 0388: Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States Abstract 0544: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study Abstract 0545: Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK) What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Dr Chao discusses Abstract 1510 at ACR22 Convergence. Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries    

Chronic opioid use is something we  encounter everyday in the perioperative setting. It can be confusing managing these patients! Do we hold their meds? Cancel the case? Unfortunately, there is varying literature supporting different practices but hopefully this episode will help you understand the WHY behind these conversations. To access all of our content, download the CORE Anesthesia App available hereon the App Store and here on Google Play. Want to connect? Check out our instagram or email us at info@coreanesthesia.com Support the show